Clinical trials: Amyloid Pathology
Gingival Inflammation, Plaque
The Effectiveness of Brushing and Flossing Sequence on Control of Plaque and Gingival Inflammation
This study evaluates the effectiveness of brushing and flossing sequence in the control of dental plaque and gingival inflammation.
- Conditions
- Gingival Inflammation, Plaque, Gingival Bleeding, Plaque Control
- Trial name
- RCT (NCT03989427)
- Testing
- Brushing first and Flossing later (BF), Flossing first and Brushing later (FB)
- Where
- Malaysia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Melaka Manipal Medical College
Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Hereditary Transthyretin Amyloidosis using data that already exist in patients' medical records.
- Trial name
- NCT05139680
- Testing
- tafamidis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Periodontal Diseases
Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical and Surgical Treatment of Teeth With Periodontal Disease
The purpose of this study is to compare clinical outcomes after mechanical debridement of at sites exhibiting plaque induced inflammation with or without adjunctive Antimicrobial photodynamic therapy (aPDT) and to assess the the…
- Trial name
- NCT05252000
- Testing
- mechanical debridement, adjunctive aPDT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center, Houston
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Gingivitis, Supragingival Plaque
Evaluation of the Efficacy and Safety of a Loop Stretchable Dental Floss
This will be a single-blind, single-center, parallel, randomized controlled clinical trial to evaluate the efficacy and safety of Floss Loops stretchable floss for the control of gingivitis and supragingival plaque removal…
- Trial name
- NCT06515483
- Testing
- Brushing and Flossing of teeth, Brushing Only
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Indiana University
Cardiac Amyloidosis
Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
The primary aim of this pilot study is to determine whether amyloid deposits in the heart can be measured non-invasively by F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) in 30 individuals with…
- Trial name
- NCT01683825
- Testing
- F-18 florbetapir PET
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Alzheimer Disease
Evaluating Simvastatin's Potential Role in Therapy
The purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects processes related to the development of Alzheimer's disease, including: 1) levels of a substance called beta-amyloid-42 found in the spinal…
- Trial name
- ESPRIT (NCT00486044)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Dental Plaque
Dental Office Prevention Strategies for Children
The overall goal of this study is to improve the standard of care in treating young children who often suffer from chronic caries (dental decay).
- Trial name
- NCT02004990
- Testing
- Single cleansing procedure of 10% Povidone Iodine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Alzheimer Disease
tACS for Amyloid-β Reduction in Alzheimer's Disease
Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration.
- Trial name
- NCT03290326
- Testing
- Transcranial Alternating Current Stimulation (tACS)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Dementia
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
Background: Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved.
- Trial name
- NCT03958630
- Testing
- 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer Disease, Amyloid Beta-Protein
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission…
- Trial name
- NCT00750282
- Testing
- Florbetaben (BAY94-9172)
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 422 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy.
- Trial name
- NCT00857415
- Testing
- florbetapir F 18
- Where
- 25 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Plaque-type Psoriasis
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
- Trial name
- STATURE (NCT01412944)
- Testing
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Where
- 27 sites in United States, Austria and 6 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Plaque-type Psoriasis
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
This study is designed to evaluate the proportion of patients achieving reversal of chronic plaque psoriasis at week 4 and 12 following multiple doses of secukinumab administered subcutaneously (sc) compared to placebo.
- Trial name
- NCT01537432
- Testing
- secukinumab
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals